AU Patent

AU2013285081A1 — Selective PI3K delta inhibitors

Assigned to Rhizen Pharmaceuticals AG · Expires 2015-01-22 · 11y expired

What this patent protects

The present invention relates to selective inhibitors of PI3K delta protein kinases having a lH-pyrazolo[3,4-d]pyrimidine ring system, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or …

USPTO Abstract

The present invention relates to selective inhibitors of PI3K delta protein kinases having a lH-pyrazolo[3,4-d]pyrimidine ring system, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013285081A1
Jurisdiction
AU
Classification
—
Expires
2015-01-22
Drug substance claim
No
Drug product claim
No
Assignee
Rhizen Pharmaceuticals AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.